Abstract: In alternative embodiments, provided are chimeric or recombinant anti-human B-cell maturation antigen (BCMA, or BCM) polypeptide (also called tumor necrosis factor receptor superfamily member 17 (TNERSF17)) antibodies, including products of manufacture and kits comprising them, and methods for making and using them, including for example their use in the detection or diagnosis of a cancer or other conditions. In alternative embodiments, anti-BCMA antibodies as provided herein are used together with an agent for determining whether BCMA expression or activity is reduced or absent.

Abstract: Provided are chimeric or recombinant antibodies (Ab), or antigen binding fragments thereof, or monomeric or dimeric antigen binding proteins, that can specifically bind to human LAG-3 polypeptides, including human LAG-3 polypeptides expressed on the surface of lymphocytes such as activated T cells that have infiltrated tumors or tumor infiltrating lymphocytes (TILs), and methods for making and using them.

Abstract: Provided are chimeric or recombinant antibodies (Ab), or antigen binding fragments thereof, or monomeric or dimeric antigen binding proteins, that can specifically bind to human LAG-3 polypeptides, including human LAG-3 polypeptides expressed on the surface of lymphocytes such as activated T cells that have infiltrated tumors or tumor infiltrating lymphocytes (TILs), and methods for making and using them.

Abstract: Provided are chimeric or recombinant antibodies (Ab), or antigen binding fragments thereof, or monomeric or dimeric antigen binding proteins, that can specifically bind to human LAG-3 polypeptides, including human LAG-3 polypeptides expressed on the surface of lymphocytes such as activated T cells that have infiltrated tumors or tumor infiltrating lymphocytes (TILs), and methods for making and using them.